Stock Movers Equinix Rallies, Crocs Jumps, Viking Therapeutics Gains
Feb 12, 2026
Data center revenue guidance beats spark a rally tied to rising AI-driven bookings. Footwear maker posts a strong fourth-quarter beat and raises annual targets. Biotech moves its oral obesity drug toward a Phase 3 start. Market roundup and lighthearted banter about trendy shoe accessories add color.
AI Snips
Chapters
Transcript
Episode notes
AI Demand Boosts Data Center Outlook
- Equinix's 2026 revenue guide beat analyst estimates and shares jumped double digits.
- Analysts cite increased bookings and accelerated AI demand as key drivers for data-center tailwinds.
Crocs Beats Estimates And Raises Guidance
- Crocs reported stronger-than-expected Q4 adjusted EPS and revenue, driving shares up as much as 22%.
- The company also issued annual guidance above consensus, validating recent sales momentum.
Personal Take On Crocs And Knockoffs
- Norma Linda shares a personal view that she owns a pair of Crocs and is bewildered by knockoffs flooding the market.
- She notes many buyers opt for cheaper alternatives despite Crocs' premium pricing and personalization options like 'Jibbitz'.